Skip to main
BDSX
BDSX logo

Biodesix (BDSX) Stock Forecast & Price Target

Biodesix (BDSX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biodesix Inc. demonstrates a strong financial outlook with a projected revenue growth of 30% for 2026, primarily driven by a 32% increase in lung diagnostic testing revenue and a 14% rise in development services and other revenue streams. The company’s forecast indicates an anticipated lung diagnostic testing revenue of $98 million, contingent upon successful execution of its sales force expansion strategy, which aims to increase its representatives to approximately 120 by the end of 2026. Additionally, Biodesix is noted for its sufficient capitalization and disciplined operational approach, positioning it well to achieve positive adjusted earnings in the near future.

Bears say

Biodesix Inc experienced a revenue miss in the first quarter of 2025, leading to a reduction in revenue guidance for the year, which was linked to a shift in the company's commercial strategy. This adjustment in strategy raises concerns about the company's ability to capitalize on existing market opportunities and generate consistent revenues moving forward. Given the reliance on diagnostic testing services and the potential challenges in their biopharmaceutical partnerships, the outlook appears increasingly negative for Biodesix's financial performance in the near term.

Biodesix (BDSX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biodesix (BDSX) Forecast

Analysts have given Biodesix (BDSX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Biodesix (BDSX) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biodesix (BDSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.